메뉴 건너뛰기




Volumn 16, Issue 2 I, 1996, Pages 245-252

Single-dose, placebo-controlled, phase I study of oral dolasetron

Author keywords

[No Author keywords available]

Indexed keywords

DOLASETRON MESILATE; HYDRODOLASETRON; PLACEBO; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG;

EID: 0029876098     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (18)

References (38)
  • 1
    • 0020699588 scopus 로고
    • On the receiving end - Patient perception of the side-effects of cancer chemotherapy
    • Coates A, Abraham S, Kaye SB, et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-8.
    • (1983) Eur J Cancer Clin Oncol , vol.19 , pp. 203-208
    • Coates, A.1    Abraham, S.2    Kaye, S.B.3
  • 2
    • 9444289691 scopus 로고
    • The impact of cytotoxic chemotherapy - Perspectives from patients, specialists and nurses
    • Cooper S, Georgiou V. The impact of cytotoxic chemotherapy - perspectives from patients, specialists and nurses. Eur J Cancer 1992;28A(suppl 1);S36-8.
    • (1992) Eur J Cancer , vol.28 A , Issue.1 SUPPL.
    • Cooper, S.1    Georgiou, V.2
  • 3
    • 0019378881 scopus 로고
    • Management of nausea and vomiting in the cancer patient
    • Frytak S, Moertel CG. Management of nausea and vomiting in the cancer patient JAMA 1981;245:393-6.
    • (1981) JAMA , vol.245 , pp. 393-396
    • Frytak, S.1    Moertel, C.G.2
  • 4
    • 0019457470 scopus 로고
    • Emesis as a critical problem in chemotherapy
    • Laszlo J, Lucas VS Jr. Emesis as a critical problem in chemotherapy. N Engl J Med 1981;305:948-9.
    • (1981) N Engl J Med , vol.305 , pp. 948-949
    • Laszlo, J.1    Lucas Jr., V.S.2
  • 5
    • 0021276659 scopus 로고
    • MDL-72222: A potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors
    • Fozard JR. MDL-72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol 1984;326:36-44.
    • (1984) Naunyn Schmiedebergs Arch Pharmacol , vol.326 , pp. 36-44
    • Fozard, J.R.1
  • 6
    • 0022481464 scopus 로고
    • Inhibition of cisplatin induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism
    • Miner WD, Sauger GJ. Inhibition of cisplatin induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986;88:497-9.
    • (1986) Br J Pharmacol , vol.88 , pp. 497-499
    • Miner, W.D.1    Sauger, G.J.2
  • 7
    • 0025917723 scopus 로고
    • 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis
    • 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991;42:551-68.
    • (1991) Drugs , vol.42 , pp. 551-568
    • Aapro, M.S.1
  • 8
    • 0025827739 scopus 로고
    • Ondansetron Therapeutic use as an antiemetic
    • Milne RJ, Heel RC. Ondansetron Therapeutic use as an antiemetic. Drugs 1991;41:574-95.
    • (1991) Drugs , vol.41 , pp. 574-595
    • Milne, R.J.1    Heel, R.C.2
  • 9
    • 0026409904 scopus 로고
    • Granisetron. A review of its pharmacological properties and therapeutic use as an andemetic
    • Plosker GL, Goa KL. Granisetron. A review of its pharmacological properties and therapeutic use as an andemetic. Drugs 1991,42:805-24.
    • (1991) Drugs , vol.42 , pp. 805-824
    • Plosker, G.L.1    Goa, K.L.2
  • 10
    • 0027369365 scopus 로고
    • Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic
    • Lee CR, Plosker GL, McTavish D. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993;46:925-43.
    • (1993) Drugs , vol.46 , pp. 925-943
    • Lee, C.R.1    Plosker, G.L.2    McTavish, D.3
  • 11
    • 0027257171 scopus 로고
    • Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting
    • Markham. A, Sorkin EM. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 1993;45:931-52
    • (1993) Drugs , vol.45 , pp. 931-952
    • Markham, A.1    Sorkin, E.M.2
  • 13
    • 0026642883 scopus 로고
    • Are granisetron and Ondansetron equivalent in the clinic?
    • Dilly S. Are granisetron and Ondansetron equivalent in the clinic? Eur J Cancer 1992;28A(suppl 1):S32-5.
    • (1992) Eur J Cancer , vol.28 A , Issue.1 SUPPL.
    • Dilly, S.1
  • 14
    • 0027419157 scopus 로고
    • Improved control of emesis and quality of life with ondansetron in breast cancer
    • Clavel M, Soukop M, Greenstreet YLA. Improved control of emesis and quality of life with ondansetron in breast cancer Oncology 1993,50:180-5.
    • (1993) Oncology , vol.50 , pp. 180-185
    • Clavel, M.1    Soukop, M.2    Greenstreet, Y.L.A.3
  • 15
    • 0027089738 scopus 로고
    • Efficacy of Ondansetron tablets in the management of chemotherapy-induced emesis: Review of clinical trials
    • Beck TM. Efficacy of Ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials. Semin Oncol 1992;19(6 suppl 15):20-5.
    • (1992) Semin Oncol , vol.19 , Issue.6 SUPPL. 15 , pp. 20-25
    • Beck, T.M.1
  • 16
    • 0027414795 scopus 로고
    • Efficacy of oral Ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy
    • Beck TM, Ciociola AA, Jones SE, et al. Efficacy of oral Ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 1993;118.407-13.
    • (1993) Ann Intern Med , vol.118 , pp. 407-413
    • Beck, T.M.1    Ciociola, A.A.2    Jones, S.E.3
  • 17
    • 2642629046 scopus 로고
    • 3 antagonists incorporating a novel bridged pseudopelletierine ring system
    • 3 antagonists incorporating a novel bridged pseudopelletierine ring system Act Chim Ther 1989,16:187-9
    • (1989) Act Chim Ther , vol.16 , pp. 187-189
    • Gittos, M.W.1    Fatmi, M.2
  • 22
    • 0026649674 scopus 로고
    • 3 receptor antagonists, ICS 205-930, MDL 72222, MDL 73147EF and MDL 72699
    • 3 receptor antagonists, ICS 205-930, MDL 72222, MDL 73147EF and MDL 72699 Neuropharmacology 1992,31:553-60
    • (1992) Neuropharmacology , vol.31 , pp. 553-560
    • Rodgers, R.J.1    Shepherd, J.K.2
  • 24
    • 0026659238 scopus 로고
    • 3 antagonist, facilitates latent inhibition in the rat
    • 3 antagonist, facilitates latent inhibition in the rat. Pharmacol Biochem Behav 1992;42:519-22.
    • (1992) Pharmacol Biochem Behav , vol.42 , pp. 519-522
    • Moran, P.M.1    Moser, P.C.2
  • 25
    • 0027533117 scopus 로고
    • Human dolasetron pharmacokinetics. II Absorption and disposition following single-dose oral administration to normal male subjects
    • Boxenbaum H, Gillespie T, Heck K, Hahne W. Human dolasetron pharmacokinetics. II Absorption and disposition following single-dose oral administration to normal male subjects. Biopharm Drug Dispos 1993;14:131-41.
    • (1993) Biopharm Drug Dispos , vol.14 , pp. 131-141
    • Boxenbaum, H.1    Gillespie, T.2    Heck, K.3    Hahne, W.4
  • 26
    • 0026480620 scopus 로고
    • Human dolasetron pharmacokinetics. 1 Disposition following single-dose intravenous administration to normal male subjects
    • Boxenbaum H, Gillespie T, Heck K, Hahne W. Human dolasetron pharmacokinetics. 1 Disposition following single-dose intravenous administration to normal male subjects. Biopharm Drug Dispos 1992;13:693-701.
    • (1992) Biopharm Drug Dispos , vol.13 , pp. 693-701
    • Boxenbaum, H.1    Gillespie, T.2    Heck, K.3    Hahne, W.4
  • 27
    • 0029017498 scopus 로고
    • A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers
    • Hunt TL, Cramer M, Shah A, Stewart W, Hahne WF, Benedict CR. A double-blind, placebo-controlled, dose-ranging safety evaluation of single-dose intravenous dolasetron in healthy male volunteers. J Clin Pharmacol 1995;35:705-12.
    • (1995) J Clin Pharmacol , vol.35 , pp. 705-712
    • Hunt, T.L.1    Cramer, M.2    Shah, A.3    Stewart, W.4    Hahne, W.F.5    Benedict, C.R.6
  • 28
    • 0026793409 scopus 로고
    • Toxicity and side effects of ondansetron
    • Finn AL. Toxicity and side effects of ondansetron. Semin Oncol 1992;19(4 suppl 10):53-60.
    • (1992) Semin Oncol , vol.19 , Issue.4 SUPPL. 10 , pp. 53-60
    • Finn, A.L.1
  • 29
    • 0024335838 scopus 로고
    • Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting
    • Grunberg SM, Stevenson LL, Russell CA, McDermed JE. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989;7:1137-41.
    • (1989) J Clin Oncol , vol.7 , pp. 1137-1141
    • Grunberg, S.M.1    Stevenson, L.L.2    Russell, C.A.3    McDermed, J.E.4
  • 32
    • 0027090286 scopus 로고
    • Clinical safety of ondansetron
    • Bryson JC. Clinical safety of ondansetron. Semin Oncol 1992;19(6 suppl 15):26-32.
    • (1992) Semin Oncol , vol.19 , Issue.6 SUPPL. 15 , pp. 26-32
    • Bryson, J.C.1
  • 33
    • 0026483929 scopus 로고
    • Oral ondansetron in the prevention of postoperative nausea and vomiting
    • Helmers JHJH. Oral ondansetron in the prevention of postoperative nausea and vomiting. Eur J Anaesthesiol 1992;9(suppl 6).49-54.
    • (1992) Eur J Anaesthesiol , vol.9 , Issue.6 SUPPL. , pp. 49-54
    • Helmers, J.H.J.H.1
  • 34
    • 0027078853 scopus 로고
    • Should the JT rather than the QT interval be used to detect prolongation of ventricular repolarization?
    • Zhou SH, Wong S, Rautaharju PM, Karnik N, Calhoun HP. Should the JT rather than the QT interval be used to detect prolongation of ventricular repolarization? J Electrocardiol 1993,25(suppl):131-6
    • (1993) J Electrocardiol , vol.25 , Issue.SUPPL. , pp. 131-136
    • Zhou, S.H.1    Wong, S.2    Rautaharju, P.M.3    Karnik, N.4    Calhoun, H.P.5
  • 36
    • 0001701695 scopus 로고
    • Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM): A possible drug class effect without sequelae?
    • Baltzer L, Kris MG, Hinkley L, et al. Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM): a possible drug class effect without sequelae? [abstr] Proc Am Soc Clin Oncol 1994,13:433.
    • (1994) Proc Am Soc Clin Oncol , vol.13 , pp. 433
    • Baltzer, L.1    Kris, M.G.2    Hinkley, L.3
  • 37
    • 0001436857 scopus 로고
    • Electrocardiographic changes with serotonin antagonist antiemetics: Rate of occurrence and clinical relevance
    • Lifsey DS, Gralla RJ, Clark RA, Kline RC. Electrocardiographic changes with serotonin antagonist antiemetics: rate of occurrence and clinical relevance [abstr]. Proc Am Soc Clin Oncol 1993;12:463.
    • (1993) Proc Am Soc Clin Oncol , vol.12 , pp. 463
    • Lifsey, D.S.1    Gralla, R.J.2    Clark, R.A.3    Kline, R.C.4
  • 38
    • 0025098278 scopus 로고
    • Phase I/II trial of granisetron: A novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting
    • Addehnan M, Erlichman C, Fine S, Warr D, Murray C. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting J Clin Oncol 1990,8:337-41.
    • (1990) J Clin Oncol , vol.8 , pp. 337-341
    • Addehnan, M.1    Erlichman, C.2    Fine, S.3    Warr, D.4    Murray, C.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.